09.29.11
McNEIL-PPC, Inc. and its affiliate McNeil MMP, LLC have completed the acquisition of full ownership of the Johnson & Johnson-Merck Consumer Pharmaceuticals Co. joint venture in the U.S. from Merck Sharp & Dohme Corp. The joint venture will be renamed McNeil Consumer Pharmaceuticals Co. and will continue to market products under the Pepcid, Mylanta, and Mylicon brands.
In addition, Johnson & Johnson Inc., through its McNeil Consumer Healthcare Division, has acquired from Merck Canada Inc. its partnership interest in the Canadian joint venture. McNeil Canada will continue to market and sell Pepcid, 222 and Fleet Enema in Canada.
The Lancaster, PA manufacturing facility will also transfer to McNEIL-PPC, Inc. These acquisitions provide McNeil and McNeil Canada with enhanced presence in the U.S. and Canada in the digestive health category.
In addition, Johnson & Johnson Inc., through its McNeil Consumer Healthcare Division, has acquired from Merck Canada Inc. its partnership interest in the Canadian joint venture. McNeil Canada will continue to market and sell Pepcid, 222 and Fleet Enema in Canada.
The Lancaster, PA manufacturing facility will also transfer to McNEIL-PPC, Inc. These acquisitions provide McNeil and McNeil Canada with enhanced presence in the U.S. and Canada in the digestive health category.
